Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

1.

Effective inhibition of HIV-1 production by shRNAs and siRNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats.

Scarborough RJ, Adams KL, Daher A, Gatignol A.

Antimicrob Agents Chemother. 2015 Jun 15. pii: AAC.00949-15. [Epub ahead of print]

PMID:
26077260
2.

HIV and Ribozymes.

Scarborough RJ, Gatignol A.

Adv Exp Med Biol. 2015;848:97-116. doi: 10.1007/978-1-4939-2432-5_5. Review.

PMID:
25757617
3.

HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Daniels SM, Sinck L, Ward NJ, Melendez-Peña CE, Scarborough RJ, Azar I, Rance E, Daher A, Pang KM, Rossi JJ, Gatignol A.

RNA Biol. 2015;12(2):123-35. doi: 10.1080/15476286.2015.1014759.

PMID:
25668122
4.

A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA.

Scarborough RJ, Lévesque MV, Boudrias-Dalle E, Chute IC, Daniels SM, Ouellette RJ, Perreault JP, Gatignol A.

Mol Ther Nucleic Acids. 2014 Jul 29;3:e178. doi: 10.1038/mtna.2014.31.

5.

Design and evaluation of clinically relevant SOFA-HDV ribozymes targeting HIV RNA.

Scarborough RJ, Lévesque MV, Perreault JP, Gatignol A.

Methods Mol Biol. 2014;1103:31-43. doi: 10.1007/978-1-62703-730-3_3.

PMID:
24318884
6.

Clarity in communication: "clear" speech authenticity and lexical neighborhood density effects in speech production and perception.

Scarborough R, Zellou G.

J Acoust Soc Am. 2013 Nov;134(5):3793-807. doi: 10.1121/1.4824120.

PMID:
24180789
7.

Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens.

Kellar KL, Gehrke J, Weis SE, Mahmutovic-Mayhew A, Davila B, Zajdowicz MJ, Scarborough R, LoBue PA, Lardizabal AA, Daley CL, Reves RR, Bernardo J, Campbell BH, Whitworth WC, Mazurek GH.

PLoS One. 2011;6(11):e26545. doi: 10.1371/journal.pone.0026545. Epub 2011 Nov 21.

8.

In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.

Lainé S, Scarborough RJ, Lévesque D, Didierlaurent L, Soye KJ, Mougel M, Perreault JP, Gatignol A.

RNA Biol. 2011 Mar-Apr;8(2):343-53. Epub 2011 Mar 1.

9.

Environmental factors affecting the levels of legacy pesticides in the airshed of Delaware and Chesapeake Bays, USA.

Goel A, McConnell LL, Torrents A, Kuang Z, Hapeman CJ, Meritt DW, Alexander ST, Scudlark JR, Scarborough R.

Environ Toxicol Chem. 2010 Sep;29(9):1893-906. doi: 10.1002/etc.243.

PMID:
20821646
10.

Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide.

Walsh MC, Hibbs AM, Martin CR, Cnaan A, Keller RL, Vittinghoff E, Martin RJ, Truog WE, Ballard PL, Zadell A, Wadlinger SR, Coburn CE, Ballard RA; NO CLD Study Group.

J Pediatr. 2010 Apr;156(4):556-61.e1. doi: 10.1016/j.jpeds.2009.10.011. Epub 2010 Feb 6.

11.

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.

MacFarland R, Hard ML, Scarborough R, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2010 Jan;16(1):95-101. doi: 10.1016/j.bbmt.2009.09.003. Epub 2009 Sep 10.

12.

Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitors.

Jia ZJ, Scarborough RM, Zhang P, Halfon S, Arfsten AE, Sinha U, Zhu BY.

Chem Pharm Bull (Tokyo). 2009 Sep;57(9):1004-7.

13.

Optical phonetics and visual perception of lexical and phrasal stress in English.

Scarborough R, Keating P, Mattys SL, Cho T, Alwan A.

Lang Speech. 2009;52(Pt 2-3):135-75.

PMID:
19624028
14.

Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.

Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, Lau G, Mosi RM, Neff KS, Nelson KL, Ruzek MC, Patel K, Santucci Z, Scarborough R, Wong RS, Bridger GJ, Macfarland RT, Fricker SP.

Biochem Pharmacol. 2009 Oct 15;78(8):993-1000. doi: 10.1016/j.bcp.2009.06.010. Epub 2009 Jun 18.

PMID:
19540208
15.

Characterization of the TRBP domain required for dicer interaction and function in RNA interference.

Daniels SM, Melendez-Peña CE, Scarborough RJ, Daher A, Christensen HS, El Far M, Purcell DF, Lainé S, Gatignol A.

BMC Mol Biol. 2009 May 7;10:38. doi: 10.1186/1471-2199-10-38.

16.

Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.

Zhang P, Bao L, Fan J, Jia ZJ, Sinha U, Wong PW, Park G, Hutchaleelaha A, Scarborough RM, Zhu BY.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2186-9. doi: 10.1016/j.bmcl.2009.02.114. Epub 2009 Mar 3.

PMID:
19297158
17.

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2179-85. doi: 10.1016/j.bmcl.2009.02.111. Epub 2009 Mar 3.

PMID:
19297154
18.

Talker adaptation in speech perception: adjusting the signal or the representations?

Dahan D, Drucker SJ, Scarborough RA.

Cognition. 2008 Sep;108(3):710-8. doi: 10.1016/j.cognition.2008.06.003. Epub 2008 Jul 23.

19.

Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers.

Nyunt MM, Becker S, MacFarland RT, Chee P, Scarborough R, Everts S, Calandra GB, Hendrix CW.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65. doi: 10.1097/QAI.0b013e3181627566.

PMID:
18362694
20.

Development of a MLST-biased SNP microarray for Candida albicans.

Lott TJ, Scarborough RT.

Fungal Genet Biol. 2008 Jun;45(6):803-11. doi: 10.1016/j.fgb.2008.01.005. Epub 2008 Jan 31.

PMID:
18334305
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk